Racial and ethnic disparities in androgenetic alopecia clinical trials in the USA

Background: Introduction: Androgenetic alopecia (AGA) is the most common type of hair loss worldwide and is estimated to affect about 80 million people in the United States. Recent trends suggest that incidence and severity of the disease are increasing across all genders and races. Randomized controlled trials (RCTs) involving diverse patient populations are necessary to personalize treatment. Objective: Evaluate enrollment and subgroup analysis of people falling in racial/ethnic minorities in phase II and III RCTs for AGA published in the United States within the past 10 years.